Subscribe Now Subscribe Today
Science Alert
 
FOLLOW US:     Facebook     Twitter
Blue
   
Curve Top
International Journal of Pharmacology
  Year: 2018 | Volume: 14 | Issue: 4 | Page No.: 471-476
DOI: 10.3923/ijp.2018.471.476
Curative Effects of Zoledronic Acid Combined with Calcitonin on the Treatment of Bone Metastasis and Osteoporosis in Lung Cancer
Chang-yan Xu, Song Zhao, Yi-yu Wang, Hui Sha, Jing-nan Sun, Feng-yan Jin and Feng Niu

Abstract:
Background and Objective: The role of calcitonin on cancers complicated with bone metastasis has not been reported. This study aimed to evaluate the clinical efficacy of zoledronic acid combined with calcitonin for bone metastasis and osteoporosis in patients with lung cancer. Materials and Methods: Total of 100 patients with lung cancer complicated with bone metastasis and osteoporosis were randomly and equally divided into the control group (conventional analgesic (non-opioids → mild-opioids → strong opioids), calcium and 1,25-Dihydroxycholecalciferol) and the observational group (additional zoledronic acid combined with calcitonin therapy). Then, the life quality, bone pain, activity ability, metastatic lesion, serum biochemical indicators of bone metabolism and bone mineral density (BMD) of hip joint, as well as the adverse reactions and skeletal-related events (SREs) were recorded in both two groups. The effectiveness of treatment as ordered categorical variable was measured using Mann-Whitney U method. All the data of serum indicators were expressed as the mean±SD and analyzed using paired t-test for the comparison before and after treatment. Independent samples t-test was used for the comparison between the two groups. Chi-square test was used for the comparison of incidence of adverse reactions and SREs. Results: The significant improvement of life quality, bone pain, activity ability, serum biochemical indicators of bone metabolism and BMD of hip joint were observed in the observational group compared with the control group (p<0.01). Bone metastatic lesions were significantly reduced by this combined therapy compared with conventional therapy (p<0.05). The incidences of adverse reactions and SREs in the observational group were significantly lower than that in the control group (6.0 vs. 24.0% and 4.0 vs. 22.0%, p<0.05), respectively. Conclusion: The application of zoledronic acid combined with calcitonin was significantly more effective for bone metastasis and osteoporosis in patients with lung cancer, compared with conventional therapy.
PDF Fulltext XML References Citation Report Citation
How to cite this article:

Chang-yan Xu, Song Zhao, Yi-yu Wang, Hui Sha, Jing-nan Sun, Feng-yan Jin and Feng Niu, 2018. Curative Effects of Zoledronic Acid Combined with Calcitonin on the Treatment of Bone Metastasis and Osteoporosis in Lung Cancer. International Journal of Pharmacology, 14: 471-476.

DOI: 10.3923/ijp.2018.471.476

URL: https://scialert.net/abstract/?doi=ijp.2018.471.476

 
COMMENT ON THIS PAPER
 
 
 

 

 
 
 
 
 
 
 
 
 

 
 
 
 
 
 
 
 
 
 
 

       

       

Curve Bottom